Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab
This article described a patient with metastatic bladder cancer (mBC) who was successfully treated with nab-paclitaxel plus sintilimab. Localized muscle-invasive bladder cancer (MIBC) was discovered in a 56-year-old man who received radical cystectomy and platinum-based adjuvant chemotherapy. Eleven...
Main Authors: | Zhu-lei Tao, Wei Wu, Lin-chun Liang, Jin-feng Pan, Jian-zhou Cao, Xiao-long Jia, Li Fang, Qi Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1020793/full |
Similar Items
-
The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
by: Jianzheng Wang, et al.
Published: (2022-06-01) -
Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
by: Nan Zhou, et al.
Published: (2023-08-01) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
by: Yizhao Xie, et al.
Published: (2021-11-01) -
Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01) -
Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)